

Index to Volume Twenty-five

Index of Issues: January, 1-56; February, 57-118; March, 119-180; April, 181-224; May, 225-272; July, 273-330; August, 331-394; September, 395-450; October, 451-500; November, 501-578.

INDEX OF AUTHORS

A
Agaçidan A, 448
ACSF-investigators, 437
Ajayi AO, 237
Alonso JM, 366
Ang O, 448
Aral SO, 90, 130, 232, 378, 455
Arquez JM, 569
Ashley R, 82
Augenbraun M, 1, 569
Aydin MD, 448

B
Bachmann L, 1
Ballenger A, 539
Banda M, 254
Beardsley L, 509
Beck-Sagué C, 533
Beebe JL, 265
Bell D, 303
Bellin EY, 303
Belongia EA, 169
Beltrami JF, 501
Bertrand JR, 169
Bhullar V, 533
Bianchi A, 366
Bierman R, 509
Biggar RJ, 237
Black CM, 5, 49, 225, 533
Blackwell R, 427
Blattner WA, 237
Blin P, 118
Bliss MJ, 561
Bloch J, 118
Bloom A, 427
Bogard M, 366
Bohbot JM, 366
Bolan G, 222
Boles J, 273
Borobio MV, 569
Bou-Saada I, 139
Bowden FJ, 322
Bowser B1
Branson B, 539
Branson BM, 553
Brathwaite W, 108
Brown W, 243
Bruce S, 361
Buchbinder SP, 296
Bull SS, 457
Bullard JC, 225
Burk RD, 509
Burstein GR, 395

C
Calcina A, 24
Candal DH, 225, 533
Cannon RO, 553
Capps L, 443
Carolina J, 310
Carrillo C, 82
Carré N, 476
Cates W Jr, 151
Caul O, 14
Celum C, 296
Cessot G, 366
Chama D, 254

Chan LY, 464
Chen CY, 408
Chen Z, 533
Chernesky M, 14
Cheung WM, 464
Choi ST, 211
Chong LY, 464
Clark AM, 421
Clay-Warner J, 273
Cohen DA, 501, 544
Cohen M, 527
Cohen SS, 368
Cohn DL, 353
Coles FB, 5
Connolly A-M, 20
Cook RL, 144
Corby NH, 353
Corey L, 58
Crissman CE, 132
Cristofani R, 24

D
Dada AJ, 237
Daling JR, 278, 285
Daniel R, 243
D'Souza P, 293
Davidsson S, 44
De Lallo F, 451
DeHovitz J, 49
DeMers SM, 421
Di Fabrizio N, 451
Diamondstone L, 237
Dicker LW, 251, 310
Donovan B, 505
Douglas J, 222
Douglas JM Jr, 457, 468
Doyle M, 443
Drew WL, 481
Drociuk D, 211
DuBouchet L, 1, 176
Duran R, 161
Dussaix E, 476

E
Edlin BR, 154
Ehret JM, 522
Eitrem R, 433
El-Sadr W, 443
Ellen HM, 130
Erenius M, 433
Escamilla J, 82
Estébanez P, 194
Evans P, 154
Evans T, 361

F
Facer M, 100
Farley TA, 501, 544
Farsky CE, 49, 533
Faruque S, 154
Feldman J, 49
Fenaughty AM, 38
Finelli L, 132
Fishbein M, 353
Fisher DG, 38
Fitzgerald S, 49
Ford WL, 342

Fortenberry JD, 76
Fox KK, 386
Foxman B, 90, 232
Frerichs RR, 342
Fresia AE, 331
Friedman SR, 219
Frost A, 243
Fullilove RE, 130

G
Gaydos CA, 108, 395, 406, 450
Giacomini G, 24
Girdner J, 450
Giuliani M, 221
Glanton V, 533
Glaser JB, 308
Glover LH, 139
Gollub EL, 483
Gore S, 217
Gossack JP, 265
Gotuzzo E, 82
Graham D, 303
Grant JC, 194
Gray RH, 450
Greenblatt RM, 137
Greenspan JR, 49
Gross M, 296
Grumet S, 317
Gunn RA, 49, 132, 218
Güvencer Z, 448

H
Habel LA, 278, 285
Halsey N, 331
Hamer FR 28
Hammond KR, 427
Hamrick JT, 501
Handsfield HH, 12
Haraoka M, 489
Harper SL, 218
Harrison A, 20
Hatch K, 361
Hatch S, 154
Heagerty P, 296
Hennessy M, 561
Hershaw RC, 527
Hillier SL, 421
Hillis SD, 5
Hiltunen-Back E, 181
Hira SK, 196
Ho GYF, 509
Holbrook KA, 303
Holloway B, 408
Holmes KK, 82, 90, 232
Hook EW III, 1
Hortin G, 427
Hovell MF, 49
Howell MR, 108, 406

I
Iatesta M, 222
Inciardi J, 154
Irwin KL, 154
Ismail M, 176

J
Jamkhedkar PP, 196

K
Kaceris J, 331
Kadioglu A, 448
Kalish LA, 527
Kamb M, 222
Karim SSA, 20, 346
Karlsson SM, 44
Katamine S, 516
Kautiainen H, 181
Kawagoe K, 516
Kettinger LD, 211
Khanna N, 293
Kilmarx PH, 28
Knapp JS, 425
Kobayashi I, 489
Kotloff KL, 243
Kurokawa K, 516
Kusano Y, 516

L
Labes K, 161
Landesman S, 49
Lanjewar DN, 196
Laurent AA, 211
Lawson ML, 427
Lefèvre J-C, 350
Lepri AC, 211
Leroux T, 457
Leung CS, 464
Levine WC, 225, 251, 386
Li C, 450
Liau A, 76
Libman M, 418
Limmios EA, 415, 505
Litchfield B, 5
Liu H, 408
Ljubicic M, 569
Luinstra K, 14
Lum G, 505
Lurie M, 20
LèPargneur J-P, 350

M
Macaluso M, 427
Macke BA, 561
Madger LS, 130
Maguire RA, 494
Mahony J, 14
Malkin JE, 366
Malotte K, 211
Mancuso S, 451
Manif 2000 Study Group, 483
Mann JM, 455
Martin DH, 501
Martin DL, 169

Index to Volume Twenty-five

Index of Issues: January, 1-56; February, 57-118; March, 119-180; April, 181-224; May, 225-272; July, 273-330; August, 331-394; September, 395-450; October, 451-500; November, 501-578.

INDEX OF AUTHORS

A
Agaçidan A, 448
ACSF-investigators, 437
Ajayi AO, 237
Alonso JM, 366
Ang O, 448
Aral SO, 90, 130, 232, 378, 455
Arquez JM, 569
Ashley R, 82
Augenbraun M, 1, 569
Aydin MD, 448

B
Bachmann L, 1
Ballenger A, 539
Banda M, 254
Beardsley L, 509
Beck-Sagué C, 533
Beebe JL, 265
Bell D, 303
Bellin EY, 303
Belongia EA, 169
Beltrami JF, 501
Bertrand JR, 169
Bhullar V, 533
Bianchi A, 366
Bierman R, 509
Biggar RJ, 237
Black CM, 5, 49, 225, 533
Blackwell R, 427
Blattner WA, 237
Blin P, 118
Bliss MJ, 561
Bloch J, 118
Bloom A, 427
Bogard M, 366
Bohbot JM, 366
Bolan G, 222
Boles J, 273
Borobio MV, 569
Bou-Saada I, 139
Bowden FJ, 322
Bowser B1
Branson B, 539
Branson BM, 553
Brathwaite W, 108
Brown W, 243
Bruce S, 361
Buchbinder SP, 296
Bull SS, 457
Bullard JC, 225
Burk RD, 509
Burstein GR, 395

C
Calcina A, 24
Candal DH, 225, 533
Cannon RO, 553
Capps L, 443
Carolina J, 310
Carrillo C, 82
Carré N, 476
Cates W Jr, 151
Caul O, 14
Celum C, 296
Cessot G, 366
Chama D, 254

Chan LY, 464
Chen CY, 408
Chen Z, 533
Chernesky M, 14
Cheung WM, 464
Choi ST, 211
Chong LY, 464
Clark AM, 421
Clay-Warner J, 273
Cohen DA, 501, 544
Cohen M, 527
Cohen SS, 368
Cohn DL, 353
Coles FB, 5
Connolly A-M, 20
Cook RL, 144
Corby NH, 353
Corey L, 58
Crissman CE, 132
Cristofani R, 24

D
Dada AJ, 237
Daling JR, 278, 285
Daniel R, 243
D'Souza P, 293
Davidsson S, 44
De Lallo F, 451
DeHovitz J, 49
DeMers SM, 421
Di Fabrizio N, 451
Diamondstone L, 237
Dicker LW, 251, 310
Donovan B, 505
Douglas J, 222
Douglas JM Jr, 457, 468
Doyle M, 443
Drew WL, 481
Drociuk D, 211
DuBouchet L, 1, 176
Duran R, 161
Dussaix E, 476

E
Edlin BR, 154
Ehret JM, 522
Eitrem R, 433
El-Sadr W, 443
Ellen HM, 130
Erenius M, 433
Escamilla J, 82
Estébanez P, 194
Evans P, 154
Evans T, 361

F
Facer M, 100
Farley TA, 501, 544
Farsky CE, 49, 533
Faruque S, 154
Feldman J, 49
Fenaughty AM, 38
Finelli L, 132
Fishbein M, 353
Fisher DG, 38
Fitzgerald S, 49
Ford WL, 342

Fortenberry JD, 76
Fox KK, 386
Foxman B, 90, 232
Frerichs RR, 342
Fresia AE, 331
Friedman SR, 219
Frost A, 243
Fullilove RE, 130

G
Gaydos CA, 108, 395, 406, 450
Giacomini G, 24
Girdner J, 450
Giuliani M, 221
Glanton V, 533
Glaser JB, 308
Glover LH, 139
Gollub EL, 483
Gore S, 217
Gossack JP, 265
Gotuzzo E, 82
Graham D, 303
Grant JC, 194
Gray RH, 450
Greenblatt RM, 137
Greenspan JR, 49
Gross M, 296
Grumet S, 317
Gunn RA, 49, 132, 218
Güvencer Z, 448

H
Habel LA, 278, 285
Halsey N, 331
Hamer FR 28
Hammond KR, 427
Hamrick JT, 501
Handsfield HH, 12
Haraoka M, 489
Harper SL, 218
Harrison A, 20
Hatch K, 361
Hatch S, 154
Heagerty P, 296
Hennessy M, 561
Hershaw RC, 527
Hillier SL, 421
Hillis SD, 5
Hiltunen-Back E, 181
Hira SK, 196
Ho GYF, 509
Holbrook KA, 303
Holloway B, 408
Holmes KK, 82, 90, 232
Hook EW III, 1
Hortin G, 427
Hovell MF, 49
Howell MR, 108, 406

I
Iatesta M, 222
Inciardi J, 154
Irwin KL, 154
Ismail M, 176

J
Jamkhedkar PP, 196

K
Kaceris J, 331
Kadioglu A, 448
Kalish LA, 527
Kamb M, 222
Karim SSA, 20, 346
Karlsson SM, 44
Katamine S, 516
Kautiainen H, 181
Kawagoe K, 516
Kettinger LD, 211
Khanna N, 293
Kilmarx PH, 28
Knapp JS, 425
Kobayashi I, 489
Kotloff KL, 243
Kurokawa K, 516
Kusano Y, 516

L
Labes K, 161
Landesman S, 49
Lanjewar DN, 196
Laurent AA, 211
Lawson ML, 427
Lefèvre J-C, 350
Lepri AC, 211
Leroux T, 457
Leung CS, 464
Levine WC, 225, 251, 386
Li C, 450
Liau A, 76
Libman M, 418
Limmios EA, 415, 505
Litchfield B, 5
Liu H, 408
Ljubicic M, 569
Luinstra K, 14
Lum G, 505
Lurie M, 20
LèPargneur J-P, 350

M
Macaluso M, 427
Macke BA, 561
Madger LS, 130
Maguire RA, 494
Mahony J, 14
Malkin JE, 366
Malotte K, 211
Mancuso S, 451
Manif 2000 Study Group, 483
Mann JM, 455
Martin DH, 501
Martin DL, 169

Masloboeva HA, 468
 McCormack W, 1
 McCormack WM, 176
 McCoy HV, 154
 McFarlane MM, 561
 McGill W, 222
 McGill WL, 468
 McGregor JA, 176
 McKay TL, 421
 McKnight B, 278, 285
 McMahon DJ, 317
 McQuillan GM, 225
 Meehan M, 450
 Meeuwisse A, 433
 Mertz KJ, 225
 Messiah A, 118
 Meyer L, 437, 476
 Mikaelian L, 14
 Miller K, 222
 Miller MA, 418
 Miller WC, 201
 Mills WA, 169
 Minkoff H, 49
 Misra RS, 293
 Moatti J-P, 483
 Moji K, 516
 Mojica B, 5
 Moncada J, 14
 Moran JS, 386
 Moretti D, 24
 Moreyra L, 82
 Morrison CS, 260
 Morrison EAB, 509
 Morse SA, 408
 Mlosure DJ, 251
 Mphuka S, 254
 Mulhall BP, 505
 Musaba E, 260
 Muyinda GK, 254

N
 Naccash RM, 211
 Nagafuji T, 489
 Nakashima AK, 386
 Nakayama H, 489
 Neaton JD, 443
 Neu NM, 317

O
 O'Donnell CR, 161
 O'Donnell L, 161
 Obadia Y, 483

Ortiz CG, 457

P
 Paavonen J, 14, 181
 Pandhi RK, 293
 Patton DL, 421
 Paul I, 14
 Peng G, 443
 Perea EJ, 569
 Peterman TA, 28, 310, 539, 553
 Pettus KS, 533
 Phillips DM, 494
 Piedrahita C, 139
 Pillay A, 408
 Plourde PJ, 254
 Podschun GD, 49
 Poindexter AN III, 335
 Pope V, 549
 Potterat JJ, 154
 Pálsdóttir R, 44

Q
 Quinn T, 450
 Quinn TC, 108, 237, 395, 406

R
 Rabe LK, 421
 Ramjee G, 346
 Ransom R, 553
 Rattan A, 293
 Reunala T, 181
 Rey D, 483
 Rezza G, 221
 Rhodes SD, 211
 Rietmeijer CA, 353, 455
 Robain M, 476
 Roddy RE, 151
 Rolfs R, 549
 Ronald AR, 254
 Rosenberg MJ, 144
 Rosenthal SL, 368
 Rostila T, 181
 Rothenberg RB, 154
 Rotily M, 217
 Ruiz J, 100
 Russ K, 243

S
 Saika T, 489
 Saiman L, 317
 Sales V, 418
 Salmon-Ceron D, 476

San Doval A, 161
 Sangi-Haghpeykar H, 335
 Schachter J, 14, 229
 Schilling R, 1
 Schmitt K, 5
 Schrader M, 154
 Schulz KF, 151
 Scribner RA, 544
 Seage GR III, 296
 Sellors J, 14
 SEROCO Study Group, 476
 Serwadda D, 450
 Sewankambo NK, 450
 Sha B, 527
 Shah K, 243
 Shapiro S, 243
 Sherman KJ, 278, 285
 Shlay JC, 468
 Shroff HK, 196
 Shultz TR, 415
 Shultz TR, 505
 Shuter J, 303
 Sichali-Sichinga K, 254
 Simon PA, 342
 Sinicco A, 451
 Spina M, 451
 St. Louis ME, 5, 132, 225
 Staat MA, 331
 Stamm W, 82
 Stamm WE, 12
 Stanberry LR, 368
 Steiner B, 408
 Steiner MJ, 139
 Steingrímsson Ó, 44
 Stergachis A, 278
 Stergachis A, 285
 Sterk C, 1548
 Sturm AW, 346, 408
 Sun RK, 100
 Sunkutu MR, 260
 Sweeney YTC, 421
 Swenson P, 82
 Sy FS, 211
 Syphilis and HIV Study Group, 549
 Sánchez J, 82

T
 Tabara SO, 243
 Tanaka M, 489
 Tang Y-L, 331
 Tapsall JW, 415, 505

U
 Vaccher E, 451
 Van Den Eeden SK, 278, 285

V
 Wallace T, 1
 Warner L, 273
 Warszawski J, 437
 Wasserheit JN, 378
 Wasserman SS, 243
 Waterfield G, 395
 Wawer MJ, 450
 Webb KH, 403
 Weiland C, 217
 Westhoff C, 317
 Whittington WL, 386
 Wiley DJ, 342
 Wilkinson D, 20
 Williamson J, 273
 Wilson TE, 70
 Wolitski RJ, 353
 Wong EL, 260
 Word C, 154
 Wroten JE, 310

X
 Xu K, 533

Y
 Yamamoto T, 516
 Yu CW, 464

Z
 Zacharopoulos VR, 494
 Zaidi AA, 310, 386, 553
 Zenilman J, 222, 331
 Zenilman JM, 395
 Zimet GD, 76

A

Aboriginal Canadian women, HPV infection in, 55 (letter)
 Acid phosphatase, as semen biomarker, in condom failure, 427
 Adolescents
 African American, STD incidence in, sexual behavior and, 125, 130 (editorial)
 female
 screening of, for chlamydia and gonorrhea, 395
 STDs in, racial/ethnic differences in, 125, 130 (editorial)
 topical microbicides for, 368
 high-risk, use of general health and STD services by, 457
 high-risk male, *C. trachomatis* screening in, 49
 screening for, peer outreach for, 49
 urine ligase chain reaction testing in, for *N. gonorrhoea*, 533
 Africa
 Nigeria, genital ulcer disease and HIV in sex workers in, 237
 South Africa
 sexually transmitted diseases in, health facility-based surveillance for, 20
 STD prevalence in female sex workers, 346
 African Americans
 adolescent, STD incidence in, sexual behavior and, 125, 130 (editorial)
 diversity of sexual repertoire of, high-risk behavior and, 232
 Alcohol use/abuse
 gonorrhea prevalence and, 544
 high-risk sexual behavior and, 38, 119
 underreporting of, 220, 221 (letters)
 Anal intercourse. *See also* Sexual behavior
 female STD incidence and, 90
 rectal microbicides for, 296
 unprotected, in young male homosexuals, 100
arp gene, PCR of in subtyping of *T. pallidum*, 408
 ASTDA Achievement Award, 57
 Australia, quinolone-resistant *N. gonorrhoeae* in, 415, 425 (editorial)
 Azithromycin
 for *C. trachomatis*, vs. doxycycline, 5, 12 (editorial)
 for chlamydia, test-of-cure by PCR and transcription-mediated amplification for, 366
 for gonorrhea, treatment outcome/MIC correlates for, 505

B

Bacterial vaginosis
 cervical/vaginal cytology for, 24
 in South African sex workers, 346
 Barrier contraceptives. *See also* Condoms
 for at-risk oral contraceptive users, 139
 Book review, *Clinician's Manual on Genital Herpes* (Cunningham et al.), 216
 C

Canadian Aboriginal women, HPV infection in, 55 (letter)
 Cancer, cervical, screening for, yield of in STD clinic, 368
 Carrageenan-based nonoxynol-9, 494
 Ceftibuten, for gonorrhea, 464
 Cervical abnormalities, screening for in STD clinic, yield of, 468
 Cervical cytology, for bacterial vaginosis, 24
 Cervical human papillomavirus infection
 in Canadian Aboriginal vs. non-Aboriginal women, 55 (letter)
 detection in college women, 243
 risk assessment scale for, 509
 Cervical infection, pelvic inflammatory disease and, social and behavioral correlates of, 378
 Chancroid, ciprofloxacin vs. erythromycin vs. cotrimoxazole for, 293
Chlamydia trachomatis
 tetracycline-resistant strain of, in vitro susceptibility of, 350
 urethral colonization with, 448 (letter)
Chlamydia trachomatis infection
 azithromycin for, test-of-cure by PCR and transcription-mediated amplification for, 366
 0.25% chlorhexidine gluconate gel for, 421
 contact tracing for, in Sweden, 433

doxycycline for

 vs. azithromycin, 5, 12 (editorial)
 compliance with, 1, 12 (editorial)
 enzyme-linked immunoassay for, false-positive results of, 418
 Gen-Probe PACE 2 assay for
 in male arrestees, 501
 PCR confirmation of, DNA purification in, 265
 persistence/recurrence of, behavioral vs. pharmacologic factors in, 12
 PID and, social and behavioral correlates of, 378
 prevalence of
 national probability sample survey for, 225
 positivity as proxy for, 251
 in pregnancy, in Japan, 516
 prophylactic effect of nonoxynol-9 for, 144, 151 (editorial)
 rapid detection of, by Cobas Amplicor vs. LCx, 44
 screening for, 227 (editorial)
 DNA amplification assays for, 108
 cost-effectiveness of, 403, 406 (letters)
 in middle school students, 395
 in high-risk adolescent males, 49
 in middle school students, 395
 money-saving benefits of, 53 (letter)
 national pilot survey for, 225
 prevalence-based program for, 201
 self-collected vaginal swabs for, 450 (letter)
 serologic diagnosis of, 14
 sex during menses and, 90
 in South African sex workers, 346
 in urban family planning clinic population, 317
 urine leukocyte esterase testing for, in males, 322
 0.25% Chlorhexidine gluconate gel, for *C. trachomatis*, 421
 Ciprofloxacin
 for chancroid, vs. erythromycin and cotrimoxazole, 293
 N. gonorrhoeae resistance to, 415, 425 (editorial), 522
 Client education, video-based, in urban STD clinic, 161
 Cobas Amplicor, vs. LCx, for rapid detection of *C. trachomatis*, 44
 Cocaine use
 high-risk sexual behavior and, 38, 119
 by men who have sex with men, 353
 by sex workers, 187
 HIV serostatus and STD incidence and, 70
 underreporting of, hepatitis C transmission and, 220, 221 (letters)
 College women, detection of genital HPV infection in, 243
 Commercial sex workers. *See also* Sex workers
 Compliance, with doxycycline therapy, 1, 12 (editorial)
 Condoms
 in CMV infection prevention, 481
 effectiveness of, user practices and, 273
 failure of, objective markers of, 427
 female
 awareness and use of, 222 (letter)
 long-term use of, in Zambian high-risk populations, 260
 with rectal microbicides, 296
 use of
 by at-risk oral contraceptive users, 139
 by female sex workers
 HIV prevalence and, 451
 STD prevalence and, 82
 by French prisoners having heterosexual intercourse, 217 (letter)
 by Italian sex workers, 451
 by men who have sex with men, drug abuse and, 353
 after STD diagnosis, gender differences in, 437
 by women undergoing tubal ligation, 335
 Condylomata acuminata
 interferon for, 361
 risk factors for
 in females, 285
 in males, 278
 Contact tracing. *See also* Partner notification
 for chlamydia, in Sweden, 433
 Contraceptives, barrier. *See also* Condoms

for at-risk oral contraceptive user, 139
 Cotrimoxazole, for chancroid, vs. erythromycin and ciprofloxacin, 293
 Counseling
 group, for STD/HIV prevention, 553
 for HIV-infected clients, 28
 risk assessment-based, 539
 Crack cocaine. *See* Cocaine use
 Cytology, cervical/vaginal, for bacterial vaginosis, 24
 Cytomegalovirus infection
 in HIV infection, incidence of and risk factors for, 476, 481 (editorial)
 prevention of by condoms, 481 (editorial)

D

DNA amplification assays
 in *C. trachomatis* screening, 108
 in chlamydia screening
 cost-effectiveness of, 403, 406 (letters)
 in middle school students, 395
 DNA purification, for PCR testing of Gen-Probe PACE specimens, 265
 Douching, STD incidence and, 90
 Doxycycline, for chlamydia
 vs. azithromycin, 5, 12 (editorial)
 compliance with, 1, 12 (editorial)

Drug abuse
 high-risk sexual behavior and, 38, 119
 by men who have sex with men, 353
 by sex workers, 187
 HIV serostatus and STD incidence and, 70
 underreporting of, hepatitis C transmission and, 220, 221 (letters)
 Dry sex, female STD incidence and, 90

E

Enzyme-linked immunoassay, of *C. trachomatis*, false-positive results of, 418
 Epidemiologic support, for state and local STD control programs, 132
 Epidemiology, of gonorrhea, from 1981-1996, 386
 Erythromycin, for chancroid, vs. ciprofloxacin and cotrimoxazole, 293
 Ethnicity
 diversity of sexual repertoire of, high-risk behavior and, 232
 STD incidence in adolescents and, 125, 130 (editorial)
 Ethnographic methods, in evaluation of syphilis transmission, 154

F

Family planning clinic, urban, chlamydia in, 317
 Female condom
 awareness and use of, 222 (letter)
 long-term use of, in Zambian high-risk populations, 260
 Female sex workers. *See* Sex workers
 Finland, endemic gonorrhea in, rapid decrease in, 181
 Fluoroquinolone-resistant *Neisseria gonorrhoeae*
 in Australia, 415
 in sparfloxacin-resistant isolate, 489
 French prisoners, heterosexual intercourse by, 217 (letter)

G

Gardnerella vaginalis, urethral colonization with, 448 (letter)
 Gay men. *See also* Men who have sex with men
 high-risk behavior and condom use in, 353
 rectal microbicides for, 296
 young, HIV risk factors in, 100
 Gender, high-risk behavior and
 in HIV infection, 483
 postdiagnosis persistence of, 437
 Genital human papillomavirus infection. *See* Human papillomavirus infection
 Genital ulcer disease
 due to granuloma inguinale, HIV infection and, 196
 HIV infection and, in Nigerian sex workers, 237
 Genital warts, risk factors for
 in females, 285
 in males, 278
 Gen-Probe PACE 2 assay
 for chlamydia and gonorrhea, in male arrestees, 501
 PCR confirmation of, DNA purification in, 265
 Gonococcal urethritis, bacterial pathogens in, 448 (letter)
 Gonorrhea. *See also* *Neisseria gonorrhoeae*
 alcohol availability and, 544
 azithromycin for, treatment outcome/MIC correlates for, 505
 cefixime for, 464
 demographic and geographic trends in from 1981-1996, 386
 endemic, in Finland, rapid decrease in, 181
 Gen-Probe PACE 2 assay for, in male arrestees, 501
 prophylactic effect of nonoxynol-9 for, 144, 151 (editorial)
 quinolone-resistant
 in Australia, 415, 425 (editorial)
 trends in, 415 (editorial), 425, 522
 screening for, in middle school students, 395
 in South African sex workers, 346
 sparfloxacin-resistant, 489
 urethral pathogens in, 448 (letter)
 urine leukocyte esterase testing for, in males, 322
 urine ligase chain reaction test for, 533
 Granuloma inguinale, HIV infection and, 196
 Group counseling, for STD/HIV prevention, 553

H

Haemophilus ducreyi infection, HIV infection and, in Nigerian sex workers, 237
Haemophilus influenzae, urethral colonization with, 448 (letter)
Haemophilus parainfluenzae, urethral colonization with, 448 (letter)
 Health beliefs, HIV immunization and, 76
 Health teaching, video-based, in urban STD clinic, 161
 Hepatitis C
 transmission of, underreporting of injecting drug use and, 220, 221 (letters)
 in women with or at risk for HIV infection, 527
 Herpes simplex virus infection, identification and control of, 58 (Paran Award Lecture)
 Herpes simplex virus type 2, HIV infection and, in Nigerian sex workers, 237
 Heterosexual intercourse, in French prison, 217 (letter)
 High-risk behavior. *See* Drug abuse; Sexual behavior, high-risk
 Homosexuals. *See also* Men who have sex with men
 high-risk behavior and condom use in, 353
 rectal microbicides for, 296
 sex worker. *See* Sex workers
 young, HIV risk factors in, 100
 Human immunodeficiency virus antibodies, oral fluid testing for, 211
 Human immunodeficiency virus infection
 CMV seroconversion in, incidence of and risk factors for, 476, 481 (editorial)
 female, STDs in, 443
 genital ulcer disease and, in Nigerian sex workers, 237
 hepatitis C and, 527
 high-risk behavior in, gender differences in, 483
 immunization for, health beliefs and, 76
 infection and, granuloma inguinale and, 196
 partner notification for, 310
 posttest counseling for, 28
 prevalence of, in Italian sex workers, 451
 in prison populations, 308 (editorial)
 prophylactic effect of nonoxynol-9 for, 144, 151 (editorial)
 rapid testing for, in Zambia, 254
 risk assessment-based testing and counseling for, 539
 risk factors for, in men who have sex with men, 100, 353
 screening for
 oral fluid testing for, 211
 physicians' practice and opinions regarding, 169
 social consequences of, 28
 in South African sex workers, 346
 in Spanish sex workers, workplace vs. income in prediction of, 194
 tests for, failure to receive results of, 342
 Human immunodeficiency virus serostatus, STD incidence and, in female cocaine users, 70
 Human papillomavirus infection

in Canadian Aboriginal vs. non-Aboriginal women, 55 (letter)
 genital, detection of in college women, 243
 risk assessment scale for, 509
 Human rights issues, in sex work, 455
 Human seminal plasma antigen, as semen biomarker, in condom failure, 427
 Human T-cell lymphotropic virus type I, transmission of during sexual assault, 327 (letter)

I

Immunization
 for HIV infection, health beliefs and, 76

STD clinic programs for, 331

Intercourse. *See also* Sexual behavior
 anal

female STD incidence and, 90
 rectal microbicides for, 296
 unprotected, in young male homosexuals, 100

heterosexual, in French prison, 217 (letter)

Interferon, for condylomata acuminata, 361

J

Japan, chlamydia in pregnancy in, prevalence trends for, 516

L

Leukocyte esterase test, for gonorrhea and chlamydia, in males, 322
 Ligase chain reaction test, urine, for *N. gonorrhoeae*, 533

M

Male prostitutes. *See* Sex workers

Menses, sex during, STD incidence and, 90

Men who have sex with men

high-risk behavior and condom use in, 353
 HIV risk factors in, 100, 353

Metronidazole, vaginal gel vs. oral preparations of, for *Trichomonas vaginalis* vaginitis, 176

Microbicide(s), topical

0.25% chlorhexidine gluconate gel as, 421
 for female adolescents, 368
 for gay men, 296
 nonoxynol-9, prophylactic efficacy of, 144, 151 (editorial)
 for trichomoniasis, vs. oral metronidazole for, 176

N

Neisseria gonorrhoeae. *See also* Gonorrhea

quinolone-resistant

in Australia, 415, 425 (editorial)
 trends in, 415 (editorial), 425, 522
 sparfloxacin-resistant, 489
 urine ligase chain reaction test for, 533

Network approach, in evaluation of syphilis transmission, 154

Nigerian sex workers, genital ulcer disease and HIV in, 237

Noncompliance, with doxycycline therapy, 1, 12 (editorial)

Nongonococcal urethritis, bacterial pathogens in, 448 (letter)

Nonoxynol-9

carageenan-based, 494
 prophylactic efficacy of, 144, 151 (editorial)

O

Ofloxacin

for chancroid, vs. erythromycin and cotrimoxazole, 293
N. gonorrhoeae resistance to, 415, 425 (editorial)

Oral contraceptives users, condom use by, 139

P

Pap smear, yield of, 468

Parran Award Lecture, 58

Partner notification, 218 (letter)

for chlamydia, in Sweden, 433
 four-site time allocation study of, 561
 for HIV infection, 310
 for syphilis, 218 (letter)
 social network approach in, 154

Patient education, video-based, in urban STD clinic, 161

Peer teen outreach, for *C. trachomatis* screening, in high-risk adolescent males, 49

Pelvic inflammatory disease (PID)

prevention of, in adolescents, 378, 395
 social and behavioral correlates of, 378

Polymerase chain reaction

in confirmation of Gen-Probe PACE 2 results, DNA purification in, 265
 in subtyping of *Treponema pallidum*, 408

in test-of-cure for azithromycin-treated chlamydia, 366

Post-test counseling, for HIV-infected clients, 28

Pregnancy

chlamydia in, prevalence trends for, in Japan, 516
 HIV infection and STD screening in, 137 (editorial), 169

Pregnant prisoners, trichomoniasis rates and risk factors in, 303, 308 (editorial)

Prenatal screening, for HIV infection and STDs, 137 (editorial), 169

Prisoners/arrestees

French, heterosexual intercourse by, 217 (letter)
 Gen-Probe PACE 2 assay for, for chlamydia and gonorrhea, 501

pregnant, trichomoniasis rates and risk factors in, 303, 308 (editorial)
 STDs in, 303, 308 (editorial)

Prostate specific antigen, as semen biomarker, in condom failure, 427

Prostitutes. *See* Sex workers

Q

Quinolone-resistant *Neisseria gonorrhoeae*

in Australia, 415, 425 (editorial)
 in sparfloxacin-resistant isolate, 489
 trends in, 415 (editorial), 425, 522

R

Race

diversity of sexual repertoire and high-risk behavior and, 232

STD incidence in adolescents and, 125, 130 (editorial)

Rape, human T-cell lymphotropic virus type I transmission in, 327 (letter)

Rectal microbicides, for gay men, 296

Restriction fragment length polymorphisms, in subtyping of *Treponema pallidum*, 408

Risk assessment, for improved targeting of STD clinic tests and counseling for HIV infection, 539

Risk assessment scale, for HPV infection, 509

S

Screening

for chlamydia, 227 (editorial)

DNA amplification assays for, 108

cost-effectiveness of, 403, 406 (letters)

in middle school students, 395

in high-risk adolescent males, 49

in male arrestees, Gen-Probe PACE 2 assay for, 501

money-saving benefits of, 53 (letter)

national pilot survey for, 225

prevalence-based program for, 201

in urban family planning clinic, 317

Gen-Probe PACE 2 assay in

for chlamydia and gonorrhea, in male arrestees, 501

DNA purification in PCR confirmation of, 265

for gonorrhea

in male arrestees, Gen-Probe PACE 2 assay for, 501

in middle school students, 395

for high-risk adolescents, 457

for HIV infection

failure to receive results of, 342

oral fluid testing for, 211

Pap smear, yield of, 468

prenatal, for HIV infection and STDs, 137 (editorial), 169

of prison populations, 308 (editorial)

STD reduction by, vs. by condom use, 82

for STDs, physicians' practice and opinions regarding, 169

Semen biomarkers, in condom failure, 427

Serologic diagnosis, of *C. trachomatis* infection, 14

Sex hustlers, high-risk behavior and condom use by, 353

Sexual assault, human T-cell lymphotropic virus type I transmission in, 327 (letter)

Sexual behavior, high-risk
alcohol use and, 38, 119, 544
of crack-smoking sex workers, 187
diversity of sexual repertoire and, 232
drug abuse and, 38, 119, 187
female STD incidence and, 90
in HIV infection, gender differences in, 483
postdiagnosis persistence of, gender differences in, 437
racial/ethnic differences in STD incidence and, 125
underreporting of, 220, 221 (letters)
in young male homosexuals, 100

Sexual behavior risk scale, for HPV infection, 509

Sexually transmitted disease clinics
doxycycline compliance in, 1, 12 (editorial)
failure to receive HIV test results in, 342
immunization programs in, 331
Pap smear screening in, yield of, 468
risk assessment-based HIV testing and counseling in, 539
video-based patient education in, 161

Sexually transmitted diseases
in adolescents, racial/ethnic differences in, 125
anal sex and, in females, 90
cervical atypia and, 468
douching and, 90
dry sex and, 90
in female sex workers
policy interventions for, 455 (editorial)
reduction of by condom use vs. periodic exam program, 82
health services for, use of by adolescents, 457
in HIV-infected women, 443
incidence of, HIV serostatus and, in female cocaine users, 70
persistence of high-risk behavior after diagnosis of, gender differences in, 437
in prison populations, 303, 308 (editorial)
in rural South Africa, health facility-based surveillance for, 20
screening for. *See* Screening
sex during menses and, 90
in Spanish sex workers, workplace vs. income in prediction of, 194
state and local control programs for, epidemiologic support for, 132
viral, identification and control of, 58 (Parran Award Lecture)

Sexual repertoire, diversity of, high-risk behavior and, 232

Sexual transmission, of hepatitis C, 527

Sex workers
crack-smoking, high-risk sexual behavior of, 187
Italian, HIV seroprevalence and condom use in, 451
male, high-risk behavior and condom use by, 353
Nigerian, genital ulcer disease and HIV in, 237
South African, STD prevalence in, 346
Spanish, HIV/STD status of, workplace vs. income in prediction of, 194
STDs in, reduction of by condom use vs. periodic exam program, 82

Social network approach, in evaluation of syphilis transmission, 154

Social policy, for sex work, 455

Social services, for HIV-infected clients, 28

Socioeconomic status, workplace vs. income and, 194

South Africa
STD prevalence in female sex workers, 346
STDs in, health facility-based surveillance for, 20
Spanish sex workers, HIV/STD status of, workplace vs. income in prediction of, 194
Sparfloxacin, *Neisseria gonorrhoeae* resistance to, 489

Spermicides. *See also* Topical microbicide(s)
nonoxynol-9-containing
carageenan-based, 494
prophylactic efficacy of, 144, 151 (editorial)

Sterilization, female, planned condom use after, 335

Stigmatized behaviors, underreporting of, 220, 221 (letters)

Substance abuse. *See* Alcohol use/abuse; Drug abuse

Sweden, contact tracing for chlamydia in, 433

Syphilis
HIV infection and, in Nigerian sex workers, 237
molecular subtyping of *T. pallidum* for, 408
partner notification for, 218 (letter)
social network approach in, 154
in South African sex workers, 346
transmission of, social networks and ethnographic tools in evaluation of, 154
treponemal specific tests for serodiagnosis of, 549

T

Topical microbicide(s). *See also* Spermicides
0.25% chlorhexidine gluconate gel as, 421
for female adolescents, 368
for gay men, 296
nonoxynol-9, prophylactic efficacy of, 144, 151 (editorial)
for trichomoniasis, vs. oral metronidazole for, 176

tpr gene, restriction fragment length polymorphism of, in subtyping of *T. pallidum*, 408

Transcription-mediated amplification, in test-of-cure for azithromycin-treated chlamydia, 366

Treponemal specific tests, for syphilis serodiagnosis, 549

Treponema pallidum, molecular subtyping of, 408

Trichomoniasis
in pregnant prisoners, rates of and risk factors for, 303
in South African sex workers, 346
vaginal gel vs. oral metronidazole for, 176

Tubal ligation, planned condom use after, 335

Turkey, bacterial pathogens in male urethritis patients in, 448 (letter)

U

Ulcers, genital
due to granuloma inguinale, HIV infection and, 196
HIV infection and, in Nigerian sex workers, 237

Urea urealyticum, urethral colonization with, 448 (letter)

Urethritis
bacterial pathogens in, 448 (letter)
gonococcal. *See* Gonorrhea

Urinalysis, in *C. trachomatis* screening, in high-risk adolescent males, 49

Urine leukocyte esterase testing, for gonorrhea and chlamydia, in males, 322

Urine ligase chain reaction test, for *N. gonorrhoeae*, 533

V

Vaccination
for HIV infection, health beliefs and, 76
STD clinics programs for, 331

Vaginal cytology, for bacterial vaginosis, 24

Vaginal gel metronidazole, for *Trichomonas vaginalis* vaginitis, vs. oral preparations, 176

Vaginitis
trichomonal
in pregnant prisoners, rates of and risk factors for, 303
in South African sex workers, 346
vaginal gel vs. oral metronidazole for, 176

Trichomonas vaginalis, vaginal gel vs. oral metronidazole for, 176

Vaginosis, bacterial
cervical/vaginal cytology for, 24
in South African sex workers, 346

Video-based patient education, in urban STD clinic, 161

Viral sexually transmitted diseases, identification and control of, 58 (Parran Award Lecture)

W

Warts, genital, risk factors for
in females, 285
in males, 278

Z

Zambia
long-term female condom use in, 260
rapid HIV testing in, 254